Cabergoline 0.25mg Tablet
Cabergoline 0.25mg Tablet – Generic Dostinex Starting Dose | Hyperprolactinaemia, Prolactinoma and Prolactin Control
Reviewed by a licensed endocrinologist | Last updated: April 2026 Prescription advised | Starting dose — step up after 4 weeks based on prolactin response
What It Is
Cabergoline 0.25mg is the lowest available strength and standard starting dose of cabergoline — a long-acting dopamine D2 receptor agonist and the active molecule in branded Dostinex® (Pfizer). The 0.25mg strength exists for a specific clinical reason: tolerability-driven initiation before stepping up to the effective therapeutic dose.
Available Indian brands at 0.25mg:
| Brand | Manufacturer |
|---|---|
| Cabgolin 0.25mg | Sun Pharmaceutical Industries Ltd |
| Caberkem 0.25mg | Various |
| Caberdost 0.25mg | Various |
0.25mg vs 0.5mg — The Most Searched Cabergoline Question
This is what every patient and buyer wants to know — and no competitor page answers it clearly:
| 0.25mg | 0.5mg | |
|---|---|---|
| Purpose | Starting dose — tolerability | Therapeutic maintenance dose |
| When used | Weeks 1–4 of initiation | From week 4–5 onwards |
| Prolactin reduction | Partial — insufficient for most patients long-term | Full therapeutic effect |
| Side effects | Minimised — nausea and dizziness less likely | Standard |
| Who stays on 0.25mg | Patients who are sensitive or elderly — may remain at 0.25mg if prolactin normalises | Most adult patients |
| Off-label prolactin control | Sufficient for mild prolactin elevation (bodybuilding/PCT) | Standard prolactin control dose |
Standard titration protocol:
- Weeks 1–4: 0.25mg twice weekly
- Week 5 onwards: increase to 0.5mg twice weekly if prolactin not yet normalised
- If 0.5mg insufficient after 4 more weeks: increase to 1mg twice weekly
- Maximum: 3mg per week (under specialist supervision)
The 0.25mg dose alone is sometimes sufficient when:
- Prolactin elevation is mild (e.g., borderline hyperprolactinaemia)
- The patient is elderly or highly sensitive to dopaminergic side effects
- Off-label use for moderate prolactin control during steroid cycles where lower exposure is sufficient
What It Treats
All indications are identical to the 0.5mg tablet — the 0.25mg is a dose, not a different medicine:
Hyperprolactinaemia: Elevated prolactin causing irregular periods, absent ovulation, galactorrhoea (unwanted milk production), infertility in women, or reduced testosterone, low libido, and sexual dysfunction in men.
Prolactinoma: Prolactin-secreting pituitary tumour. Cabergoline is first-line medical treatment — shrinks the tumour and normalises prolactin. Initial treatment typically starts at 0.25mg twice weekly then titrates based on prolactin response.
Female infertility caused by high prolactin: Normalising prolactin restores ovulatory cycles. Most patients start at 0.25mg and progress to 0.5mg as needed.
Inhibition of puerperal lactation: Single dose of cabergoline 1mg (four 0.25mg tablets) stops milk production after delivery, stillbirth, or miscarriage.
IVF OHSS prevention: Some protocols use 0.25mg daily for 8 days after egg retrieval in low-OHSS-risk patients (vs 0.5mg for higher-risk patients) — per individual clinic protocols.
Off-label prolactin control (bodybuilding/PCT): For men using 19-nor steroids (nandrolone, trenbolone) with mild to moderate prolactin elevation, 0.25mg twice weekly is often sufficient. Many experienced users prefer 0.25mg to minimise side effects while controlling prolactin effectively.
Dosage
| Indication | Starting Dose | After 4 Weeks |
|---|---|---|
| Hyperprolactinaemia | 0.25mg twice weekly | Increase to 0.5mg if prolactin not normalised |
| Prolactinoma | 0.25mg twice weekly | Titrate monthly based on prolactin response |
| Puerperal lactation inhibition | 1mg single dose (4 × 0.25mg) | — |
| IVF OHSS prevention | 0.25mg daily × 8 days | — |
| Off-label prolactin control | 0.25mg twice weekly | Continue or increase based on response |
Take with food to reduce nausea. Take at the same two days each week (e.g., Monday and Thursday). Prolactin levels should be checked 4 weeks after starting and monthly until normalised.
Side Effects
Identical to 0.5mg but generally milder at the lower dose — which is precisely why titration starts here:
Common: Nausea (significantly less common than at 0.5mg — the primary reason for starting at 0.25mg). Headache. Dizziness. Fatigue. Abdominal discomfort.
Uncommon: Low blood pressure. Mood changes. Constipation.
Serious (prolonged high-dose use only): Cardiac valve thickening — not clinically relevant at 0.25mg or standard prolactin-lowering doses. Relevant only at Parkinson's disease doses (3mg+/day).
FAQ
Should I start with 0.25mg or 0.5mg cabergoline? Standard medical practice starts at 0.25mg twice weekly for the first 4 weeks — then steps up to 0.5mg twice weekly if prolactin is not yet normalised. Starting at 0.25mg dramatically reduces nausea and tolerability issues. Never jump to 0.5mg or 1mg without physician guidance.
Will 0.25mg cabergoline be enough to lower my prolactin? For mild hyperprolactinaemia, 0.25mg twice weekly may normalise prolactin completely. For moderate-to-severe elevation or prolactinoma, most patients require 0.5mg or higher. Your doctor will adjust based on your prolactin level at the 4-week follow-up.
Is 0.25mg enough for bodybuilding prolactin control? For mild prolactin elevation from 19-nor steroid use, 0.25mg twice weekly is often sufficient. Users with higher prolactin elevations or more aggressive cycles may require 0.5mg twice weekly. Always test prolactin levels before assuming you need higher doses.
Is the 0.25mg tablet the same as half a 0.5mg tablet? Functionally yes — splitting a scored 0.5mg tablet produces approximately 0.25mg. However, the 0.25mg tablet provides a more accurate and convenient dose. Manufactured 0.25mg tablets from reputable Indian generics (Cabgolin) are preferred over splitting for accuracy.
Do you ship cabergoline 0.25mg internationally? Yes — to USA, UK, UAE.
References
- Cabergoline Dosing and Titration — Drugs.com (Updated 2025) https://www.drugs.com/dosage/cabergoline.html
- Cabergoline — DrugBank DB00248 https://go.drugbank.com/drugs/DB00248
- Cabergoline for Hyperprolactinaemia — Cochrane Review https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006578/full
